Literature DB >> 9921939

Mesorectal lymph node dissection: is it beneficial?

W Hohenberger1, C H Schick, J Göhl.   

Abstract

Locoregional recurrences and distant metastases are the determinants of the long-term prognosis following curative resection of rectal carcinoma. While distant metastases cannot be affected by the surgical treatment of the primary tumor, avoidance of local recurrence by the surgeon is of special significance as the predominant prognostic factor. Analysis of the long-term results achieved by various surgeons led to the concept of mesorectal excision - the removal of the rectum together with all additional tissue invested by the adjacent visceral fascia, that is, fatty tissue, lymph nodes, and lymphatic vessels, by sharp dissection of the appropriate anatomical plane. In our own patient material the 5-year survival rate following R0 resection was 85% for all stages, provided no local recurrence developed. This contrasts with a figure of only 23% in those who did develop local recurrence. The local recurrence rate decreased from 39.4%, with a 50% 5-year survival rate in 1974, to 9.8% and a 71% survival rate in 1991, although the rate of distant metastases remained constant. Among the patients treated between 1988 and 1994 the local recurrence rate was determined by depth of infiltration (1987 UICC classification: pT1 0%, pT2 10%, pT3 14%, pT4 28%), extent of lymph node infiltration (pN0 6%, pN1 15%, pN2 26%, pN3 25%), grading (G1 9%, G2 12%, G3 21%), and location within the rectum (upper third 13%, middle third 8%, lower third 17%), with combinations of unfavorable initial factors leading to higher local recurrence rates. The elevated local recurrence rates seen in the 1970s, in particular in the case of tumors of the lower third, were traced retrospectively to incomplete mesorectal excision, the implementation of which reduced the local recurrence rate initially to less than 10%, and then to the current 4.1%. From the oncological point of view, mesorectal excision must be considered to confer considerable benefit. In the case of carcinomas of the upper third of the rectum, mesorectal resection carried out to just 5 cm below the lower tumor edge is sufficient, however, without coning, while deeper carcinomas mandate total mesorectal excision.

Entities:  

Mesh:

Year:  1998        PMID: 9921939     DOI: 10.1007/s004230050152

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  7 in total

1.  Nodal spread and micrometastasis within mesorectum.

Authors:  Cun Wang; Zong-Guang Zhou; Zhao Wang; Dai-Yun Chen; Yang-Chun Zheng; Gao-Ping Zhao
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  [Open surgery of the rectum].

Authors:  W Hohenberger
Journal:  Chirurg       Date:  2007-08       Impact factor: 0.955

3.  Laparoscopic-assisted approach in rectal cancer patients: lessons learned from >200 patients.

Authors:  S Delgado; D Momblán; L Salvador; R Bravo; A Castells; A Ibarzabal; J M Piqué; A M Lacy
Journal:  Surg Endosc       Date:  2004-08-26       Impact factor: 4.584

4.  [Lymphadenectomy with tumors of the lower gastrointestinal tract].

Authors:  W Hohenberger; S Merkel; K Weber
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

5.  Local recurrence and survival after laparoscopic mesorectal resection forrectal adenocarcinoma.

Authors:  E C Poulin; C M Schlachta; R Grégoire; P Seshadri; M O Cadeddu; J Mamazza
Journal:  Surg Endosc       Date:  2002-02-28       Impact factor: 4.584

Review 6.  [Surgical therapy of rectal carcinoma].

Authors:  H-P Bruch; O Schwandner; R Keller; S Farke; T H K Schiedeck
Journal:  Chirurg       Date:  2003-10       Impact factor: 0.955

7.  Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy: do randomized studies translate into clinical routine?

Authors:  Ludwig Keilholz; Mesud Mese; Klaus Henneking; Jochen Willner
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.